Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
Open Access
- 26 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Toll-like receptor (TLR) agonists have received considerable attention as therapeutic targets for cancer immunotherapy owing to their ability to convert immunosuppressive tumor microenvironments towards a more T-cell inflamed phenotype. However, TLRs differ in their cell expression profiles and intracellular signaling pathways, raising the possibility that distinct TLRs differentially influence the tumor immune microenvironment. Using single-cell RNA-sequencing, we address this by comparing the tumor immune composition of B16F10 melanoma following treatment with agonists of TLR3, TLR7, and TLR9. Marked differences are observed between treatments, including decreased tumor-associated macrophages upon TLR7 agonist treatment. A biased type-1 interferon signature is elicited upon TLR3 agonist treatment as opposed to a type-2 interferon signature with TLR9 agonists. TLR3 stimulation was associated with increased macrophage antigen presentation gene expression and decreased expression of PD-L1 and the inhibitory receptors Pirb and Pilra on infiltrating monocytes. Furthermore, in contrast to TLR7 and TLR9 agonists, TLR3 stimulation ablated FoxP3 positive CD4 T cells and elicited a distinct CD8 T cell activation phenotype highlighting the potential for distinct synergies between TLR agonists and combination therapy agents.Keywords
Funding Information
- Pfizer
This publication has 28 references indexed in Scilit:
- Trial Watch: experimental TLR7/TLR8 agonists for oncological indicationsOncoImmunology, 2020
- Trial Watch: Toll-like receptor agonists in cancer immunotherapyOncoImmunology, 2018
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyOncoImmunology, 2015
- Toll‐Like ReceptorsCurrent Protocols in Immunology, 2015
- Toll-Like Receptor Signaling PathwaysFrontiers in Immunology, 2014
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapyOncoImmunology, 2012
- TLR signalling regulated antigen presentation in dendritic cellsCurrent Opinion in Immunology, 2010
- TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCGJournal of Leukocyte Biology, 2003
- Toll-Like ReceptorsAnnual Review of Immunology, 2003
- The Plasticity of Dendritic Cell Responses to Pathogens and Their ComponentsScience, 2001